HK1201196A1 - 眼病的治療 - Google Patents
眼病的治療Info
- Publication number
- HK1201196A1 HK1201196A1 HK15101784.1A HK15101784A HK1201196A1 HK 1201196 A1 HK1201196 A1 HK 1201196A1 HK 15101784 A HK15101784 A HK 15101784A HK 1201196 A1 HK1201196 A1 HK 1201196A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- ocular disease
- ocular
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161546708P | 2011-10-13 | 2011-10-13 | |
PCT/US2012/060263 WO2013056233A1 (en) | 2011-10-13 | 2012-10-15 | Treatment of ocular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201196A1 true HK1201196A1 (zh) | 2015-08-28 |
Family
ID=48082580
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101828.9A HK1201438A1 (zh) | 2011-10-13 | 2015-02-18 | 眼病的治療 |
HK15101784.1A HK1201196A1 (zh) | 2011-10-13 | 2015-02-18 | 眼病的治療 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101828.9A HK1201438A1 (zh) | 2011-10-13 | 2015-02-18 | 眼病的治療 |
Country Status (11)
Country | Link |
---|---|
US (5) | US8999325B2 (zh) |
EP (2) | EP2766044B1 (zh) |
JP (5) | JP2014532072A (zh) |
CN (2) | CN107080843A (zh) |
AU (1) | AU2012323849B2 (zh) |
BR (1) | BR112014008759A8 (zh) |
CA (1) | CA2850824C (zh) |
ES (1) | ES2774972T3 (zh) |
HK (2) | HK1201438A1 (zh) |
MX (1) | MX347226B (zh) |
WO (1) | WO2013056233A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
WO2011057112A1 (en) | 2009-11-06 | 2011-05-12 | Akebia Therapeutics Inc. | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
BR112014008819A8 (pt) | 2011-10-13 | 2017-09-12 | Aerpio Therapeutics Inc | Métodos para o tratamento de síndrome de vazamento vascular e câncer |
JP2014532072A (ja) | 2011-10-13 | 2014-12-04 | エアピオ セラピューティックス, インコーポレイテッド | 眼疾患の治療 |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
GB2516561B (en) | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
CN113248613A (zh) * | 2014-01-15 | 2021-08-13 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN结合性质的Fc区变体 |
WO2015126860A1 (en) | 2014-02-19 | 2015-08-27 | Aerpio Therapeutics, Inc. | Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones |
CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
US20160082129A1 (en) * | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
MX2019000727A (es) | 2016-07-20 | 2019-05-02 | Aerpio Therapeutics Inc | Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b). |
CN109996440A (zh) * | 2016-10-21 | 2019-07-09 | 曼宁研究有限公司 | Ve-ptp敲除 |
CN106491911A (zh) * | 2016-10-24 | 2017-03-15 | 严成 | 一种治疗脉络膜血管瘤的中药 |
JP2022502367A (ja) | 2018-09-24 | 2022-01-11 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体 |
CN114269341A (zh) | 2019-04-29 | 2022-04-01 | 视点制药公司 | 靶向施莱姆管的Tie-2激活剂 |
US11413242B2 (en) | 2019-06-24 | 2022-08-16 | EyePoint Pharmaceuticals, Inc. | Formulations of Tie-2 activators and methods of use thereof |
TW202317613A (zh) * | 2019-08-06 | 2023-05-01 | 美商建南德克公司 | 眼科疾病之個人化治療 |
CN112322719A (zh) * | 2020-11-06 | 2021-02-05 | 温州医科大学 | 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
DE69829891T2 (de) * | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
ATE241380T1 (de) | 1999-03-26 | 2003-06-15 | Regeneron Pharma | Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren |
EP1046715A1 (en) * | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
EP1292335B1 (en) | 2000-06-23 | 2007-05-30 | Bayer Schering Pharma Aktiengesellschaft | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
US6316109B1 (en) | 2000-09-21 | 2001-11-13 | Ppg Industries Ohio, Inc. | Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers |
KR20110025239A (ko) * | 2001-09-28 | 2011-03-09 | 산텐 세이야꾸 가부시키가이샤 | 약물-폴리에틸렌글리콜 결합체를 함유하는 안조직 내 주입제 |
US20030158083A1 (en) * | 2002-02-08 | 2003-08-21 | The Procter & Gamble Company | Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
JPWO2004106542A1 (ja) * | 2003-05-29 | 2006-07-20 | 三共株式会社 | インスリン抵抗性改善剤及びそのスクリーニング方法 |
US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
EP1838733B1 (en) | 2004-12-21 | 2011-08-24 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
JP2006210811A (ja) * | 2005-01-31 | 2006-08-10 | Nippon Steel Chem Co Ltd | プリント配線板の製造方法 |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
NZ569787A (en) | 2005-12-15 | 2011-07-29 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer |
BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
WO2008127727A1 (en) * | 2007-04-13 | 2008-10-23 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
JP2010531896A (ja) * | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのMetAP−2阻害剤ポリマーソーム |
WO2009006112A1 (en) | 2007-06-29 | 2009-01-08 | Schering Corporation | Mdl-1 uses |
ES2507078T3 (es) * | 2007-08-16 | 2014-10-14 | Santen Pharmaceutical Co., Ltd | Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad |
RU2010120674A (ru) | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
CA2838846C (en) * | 2009-01-12 | 2018-06-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating brain edema |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
MY176514A (en) | 2010-10-07 | 2020-08-12 | Aerpio Therapeutics Inc | Compositions and methods for treating ocular edema, neovascularization and related diseases |
BR112014008819A8 (pt) | 2011-10-13 | 2017-09-12 | Aerpio Therapeutics Inc | Métodos para o tratamento de síndrome de vazamento vascular e câncer |
JP2014532072A (ja) | 2011-10-13 | 2014-12-04 | エアピオ セラピューティックス, インコーポレイテッド | 眼疾患の治療 |
GB2516561B (en) | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
MX2019000727A (es) * | 2016-07-20 | 2019-05-02 | Aerpio Therapeutics Inc | Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b). |
JP2022502367A (ja) * | 2018-09-24 | 2022-01-11 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体 |
-
2012
- 2012-10-15 JP JP2014535978A patent/JP2014532072A/ja not_active Withdrawn
- 2012-10-15 CN CN201710084072.2A patent/CN107080843A/zh active Pending
- 2012-10-15 US US13/652,154 patent/US8999325B2/en active Active
- 2012-10-15 ES ES12840725T patent/ES2774972T3/es active Active
- 2012-10-15 MX MX2014004449A patent/MX347226B/es active IP Right Grant
- 2012-10-15 BR BR112014008759A patent/BR112014008759A8/pt not_active Application Discontinuation
- 2012-10-15 WO PCT/US2012/060263 patent/WO2013056233A1/en active Application Filing
- 2012-10-15 AU AU2012323849A patent/AU2012323849B2/en active Active
- 2012-10-15 CN CN201280054482.8A patent/CN104066448A/zh active Pending
- 2012-10-15 EP EP12840725.1A patent/EP2766044B1/en active Active
- 2012-10-15 CA CA2850824A patent/CA2850824C/en active Active
- 2012-10-15 EP EP18202143.6A patent/EP3501536A1/en active Pending
-
2015
- 2015-02-18 HK HK15101828.9A patent/HK1201438A1/zh unknown
- 2015-02-18 HK HK15101784.1A patent/HK1201196A1/zh unknown
- 2015-02-20 US US14/627,463 patent/US20150232575A1/en not_active Abandoned
-
2016
- 2016-09-13 JP JP2016178593A patent/JP2016210812A/ja not_active Withdrawn
- 2016-09-13 JP JP2016178592A patent/JP6259503B2/ja active Active
-
2017
- 2017-03-20 US US15/463,340 patent/US10329357B2/en active Active
-
2018
- 2018-05-30 JP JP2018103592A patent/JP2018131466A/ja active Pending
- 2018-05-30 JP JP2018103593A patent/JP2018131467A/ja active Pending
-
2019
- 2019-04-26 US US16/395,972 patent/US20200010565A1/en not_active Abandoned
-
2020
- 2020-01-24 US US16/751,824 patent/US20200231703A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1201438A1 (zh) | 2015-09-04 |
JP2016210812A (ja) | 2016-12-15 |
EP2766044A1 (en) | 2014-08-20 |
JP2016210811A (ja) | 2016-12-15 |
CA2850824A1 (en) | 2013-04-18 |
US20180044432A1 (en) | 2018-02-15 |
EP3501536A1 (en) | 2019-06-26 |
EP2766044A4 (en) | 2015-06-10 |
ES2774972T3 (es) | 2020-07-23 |
EP2766044B1 (en) | 2019-12-11 |
US10329357B2 (en) | 2019-06-25 |
JP2018131467A (ja) | 2018-08-23 |
WO2013056233A1 (en) | 2013-04-18 |
NZ623275A (en) | 2016-05-27 |
CN104066448A (zh) | 2014-09-24 |
US20200010565A1 (en) | 2020-01-09 |
BR112014008759A8 (pt) | 2017-09-12 |
AU2012323849A1 (en) | 2014-04-17 |
JP2018131466A (ja) | 2018-08-23 |
US20130095105A1 (en) | 2013-04-18 |
US20150232575A1 (en) | 2015-08-20 |
MX347226B (es) | 2017-04-19 |
CN107080843A (zh) | 2017-08-22 |
AU2012323849B2 (en) | 2017-04-20 |
CA2850824C (en) | 2023-01-03 |
BR112014008759A2 (pt) | 2017-06-13 |
US8999325B2 (en) | 2015-04-07 |
JP6259503B2 (ja) | 2018-01-10 |
MX2014004449A (es) | 2014-11-10 |
US20200231703A1 (en) | 2020-07-23 |
JP2014532072A (ja) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1201438A1 (zh) | 眼病的治療 | |
EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
EP2670434A4 (en) | TREATMENT OF TAUOPATHIA | |
ZA201301601B (en) | Treatment of diseases | |
SG2014008080A (en) | Methods of treatment of retinal degeneration diseases | |
EP2613786A4 (en) | TREATMENT OF DISEASES | |
EP2717855A4 (en) | PROCESSING METHODS | |
ZA201309557B (en) | Methods of treatment for retinal diseases | |
HK1199261A1 (zh) | 用於治療疾病的方法 | |
EP2623494A4 (en) | AGENT FOR THE TREATMENT OF OCULAR DISEASES | |
EP2906295A4 (en) | METHODS OF TREATING OCULAR DISEASES | |
EP2704723A4 (en) | TREATMENT OF POLYCYSTIC DISEASES | |
IL230960A0 (en) | A device for the treatment of eye disease | |
IL235874A0 (en) | Treatment of ocular inflammatory diseases by laquinimod | |
EP2544686A4 (en) | COMBINED METHODS FOR THE TREATMENT OF DISEASES | |
IL230959A0 (en) | A device for the treatment of eye disease | |
ZA201308176B (en) | Therapeutic treatment | |
GB201107467D0 (en) | Novel treatment of pain | |
LT2704747T (lt) | Akių lašai, skirti konjuktivochalazės gydymui | |
GB201204645D0 (en) | Treatment of disease | |
EP2696872A4 (en) | TREATMENT OF GLAUCOMA | |
EP2911662A4 (en) | METHOD OF TREATING A DISEASE | |
GB201118269D0 (en) | Treatment of cardiovascular disease | |
GB201107988D0 (en) | Treatment of cardiovascular disease |